Evoke Pharma Granted FDA Market Exclusivity for GIMOTI® Read more about Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®
Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List Read more about Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List
Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape Read more about Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results Read more about Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 Read more about Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022 Read more about Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI Read more about Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference Read more about Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
Evoke Pharma Reports Third Quarter 2021 Financial Results Read more about Evoke Pharma Reports Third Quarter 2021 Financial Results